Bimekizumab (Bimzelx; UCB Pharma) was approved by the FDA to treat psoriatic arthritis (PsA) on September 23, 2024, based on ...

Emerging evidence supports the argument that psoriatic arthritis arises from two pathways and that affected immune cells may ...

DMARDs are often used to treat RA and inflammatory types of arthritis, such as ankylosing spondylitis, psoriatic arthritis ...

Across 2024, our top news in immunology was concentrated in 4 disease states—ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis (RA), and axial spondyloarthritis (axSpA)—and ...

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

New trials in three new indications have been initiated with the Nanobody® sonelokimab: Phase 3 VELA-TEEN trial in adolescent ...

Even after a flurry of corporate updates during the first two days of the J.P. Morgan Healthcare Conference, many more ...

Shares of AbbVie Inc. (NYSE:ABBV – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the ...

Secukinumab is under clinical development by Novartis and currently in Phase II for Unspecified Dermatological Disorders.

The Department for Work and Pensions (DWP) has confirmed that over 1.1 million adults across Great Britain are now receiving ...